When Success Becomes Risk

Dr. Toni

5 days ago

4 min read

The Hidden Danger of Strategic Concentration

A specialty clinic is outperforming every other service line. One physician generates a substantial share of revenue. A referral partner consistently delivers high-value patients. One geographic market drives most of the group’s growth.

The leadership response seems obvious: invest more.

Expand the specialty. Recruit around the star physician. Strengthen the referral relationship. Open another location in the same market.

Each decision may be commercially rational. But together, they can create a business that looks stronger on its financial dashboard while becoming more vulnerable underneath.

When does doubling down on what works become a risk to the organization’s future?

The Success Trap

Concentration is not inherently a mistake. Focus can create expertise, scale, stronger market positioning, and better returns. The danger emerges when the organization confuses current performance with permanent reliability.

Consider four forms of concentration in healthcare:

Physician concentration: A small number of clinicians generate a disproportionate share of revenue or patient demand.
Specialty concentration: Financial performance depends heavily on one clinical service or treatment category.
Referral concentration: Patient volumes rely on a narrow network of referrers, corporate contracts, or other channels.
Geographic concentration: Growth and earnings depend on one location, catchment area, or market segment.

Each creates a different vulnerability. A physician may leave, reduce clinical hours, or become unavailable. Referral patterns may change. Competition or regulation may alter the economics of a specialty. A local market may become saturated.

The issue is not whether these events are certain. It is whether the business could withstand them without destabilizing its performance.

In “Managing Risks: A New Framework” (Harvard Business Review, June 2012), Robert S. Kaplan and Anette Mikes distinguish among different categories of risk and argue for managing them according to their nature. For healthcare leaders, that distinction matters: a concentration risk embedded in the business model cannot always be addressed by routine operational controls.

The Metrics May Be Telling Only Half the Story

A group can report rising revenue, strong margins, and growing patient volumes while its underlying exposure increases.

Why? Most performance dashboards emphasize what the organization earns. They may not reveal how dependent those earnings are on a handful of people, services, relationships, or locations.

Boards should therefore look beyond the size of a revenue stream to its concentration, substitutability, and recoverability.

Concentration: How much performance depends on one source?
Substitutability: If that source disappears, how quickly can the organization replace its contribution?
Recoverability: Could the business maintain quality, cash flow, and operations during the transition?

A physician who generates 30% of a clinic’s revenue is not automatically a problem. But if that physician also holds key referral relationships, mentors junior clinicians, and delivers a specialty service that no one else can provide, the exposure may be much greater than the revenue percentage suggests.

The risk lies in the connections between dependencies—not simply in any single number.

Five Questions for the Boardroom

Before committing more capital to an already successful area, ask:

How dependent are we on our strongest revenue drivers? Examine the share of revenue, margin, patient demand, and strategic capability tied to individual sources.
What happens if our top-performing physician or referral channel disappears? Model the likely operational and financial impact, not just the immediate revenue loss.
Are we investing in durable capability—or deepening dependency? Does the next investment create a broader, more resilient organization, or make one source even more indispensable?
When does doubling down on what works become a risk to our future? Identify the point at which additional concentration creates more exposure than advantage.
What level of diversification is worth its cost? Resilience matters, but spreading investment too thinly can dilute expertise and weaken returns. The objective is deliberate balance, not diversification for its own sake.

These are particularly important questions for healthcare investors, owners, and boards evaluating acquisitions, specialty expansion, physician partnerships, and multi-site growth.

Protect the Advantage Without Becoming Dependent on It

The answer is not to abandon the strongest specialty or stop investing in excellent physicians. It is to ensure the organization can preserve its advantage if conditions change.

That may mean developing a deeper clinical bench, building alternative referral channels, creating transferable operating capabilities, or testing adjacent markets before making large commitments. It also means defining acceptable concentration levels and agreeing what evidence would trigger a reassessment.

Strategic allocation should fund success—but also recognize when further concentration creates a vulnerability the organization cannot easily reverse.

Phoenix MedStrategy helps healthcare leaders examine the dependencies behind growth, evaluate the resilience of their business model, and anticipate risks before a successful strategy becomes a single point of failure.

The executive test: Are you strengthening your competitive advantage—or making the organization increasingly dependent on it?

The strongest business is not necessarily the one with the most concentrated success. It is the one that can sustain its advantage when the conditions supporting that success change.